[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Technische Universität Dresden\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":699},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,44,0,25,[9,47,70,100,121,146,165,189,211,235,259,291,322,345,375,405,430,487,513,541,570,592,612,634,666],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100561856","intelligent-lung-support-in-the-intensive-care-unit-100561856",false,"NCT06595602","Intelligent Lung Support in the Intensive Care Unit","Intelligent Lung Support in the Intensive Care Unit (IntelliLung): An Observational, Prospective, Multicentre Study","IntelliLung","Inclusion Criteria:\n\n1. Male and female patients, age ⪰18 years\n2. Written informed consent\n3. Invasively mechanically ventilated patients expected to be intubated for more than 24 hours.\n\nExclusion Criteria:\n\n1. Expected to die within ≤48 hours\n2. Participation in an interventional mechanical ventilation trial\n3. Mechanical Ventilation with a closed-loop ventilation mode\n4. Persons dependent on the sponsor and\u002For investigator\n5. Subjects who are currently imprisoned or otherwise in confinement ordered by law or other official authorities","ALL","18 Years",{"count":21,"type":22},530,"ESTIMATED","OBSERVATIONAL","The aim of this observational study is to test the IntelliLung decision support system based on artificial intelligence. This system is intended to help to set the ventilator. The study includes patients with and without ARDS (acute respiratory distress syndrome) who are receiving invasive mechanical ventilation, as well as patients with additional extracorporeal lung support. The study will be conducted in several centers.\n\nThe main question of the study:\n\nHow well do the mechanical ventilation settings of healthcare staff match the recommendations of the IntelliLung system?",[26,27],"Mechanical Ventilation","Intensive Care Medicine",[29,30,31,32,33],"Invasive mechanical ventilation","Intensive care medicine","critical care medicine","artificial intelligence","decision support","RECRUITING","2026-06-30",{"date":37,"type":38},"2026-07-02","ACTUAL",{"date":40,"type":38},"2025-05-25",{"date":42,"type":22},"2027-12",{"name":44,"class":45},"Technische Universität Dresden","OTHER",5,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":53,"targetDuration":55,"studyType":23,"phases":4,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100545097","multicenter-interdisciplinary-national-vexas-registry-with-accompanying-biomaterial-collection-100545097","NCT06377462","Multicenter, Interdisciplinary National VEXAS Registry With Accompanying Biomaterial Collection","Inclusion Criteria:\n\n* Patients with established or suspected (clinical and hematological criteria) VEXAS Syndrome\n* Age ≥18 years\n* Signed informed consent form\n\nExclusion Criteria:\n\n* patients who are not in a position to understand the nature and scope of participation in this register",{"count":54,"type":22},500,"5 Years","The aim is rapid collection of real-life data on the epidemiology, treatment and disease course in patients with VEXAS syndrome during routine clinical practice and collect biomaterials to evaluate genotype-phenotype associations, determine optimal treatment schedule, identify diagnostic features and biomarkers",[58],"VEXAS Syndrome",[60],"VEXAS","2026-05-13",{"date":63,"type":38},"2026-05-15",{"date":65,"type":38},"2024-03-13",{"date":67,"type":22},"2030-12-31",{"name":44,"class":45},17,{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":4},"100636127","phase-2-a-trial-for-the-treatment-of-advanced-large-cell-neuroendocrine-cancer-of-the-lung-100636127","NCT07561645","A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung","A Phase II, Single-arm Trial on the Addition of the DLL3xCD3 Bispecific T-cell Engager Obrixtamig (BI 764532) to Standard-of-care Platinum-based First-line Treatment of Advanced Large-cell Neuroendocrine Carcinoma of the Lung","ALPINE 2","Inclusion Criteria: (main criteria)\n\n1. Patient has provided written informed consent and is able to consent\n2. Patients with pulmonary large-cell neuroendocrine carcinoma (LCNEC) defined by local histology and immunohistochemistry; patients with mixed histology are eligible if LCNEC is the predominant histology, i.e. ≥50%\n3. Patients with locally advanced or metastatic disease without curative treatment options\n4. All patients must have received one, but not more than one, cycle of platinum\u002Fetoposide chemotherapy with or without immune checkpoint inhibitor (standard-of-care; SoC). Other than that, patients must be previously untreated with systemic therapy.\n5. Measurable disease according to RECIST v1.11\n\nExclusion Criteria: (main criteria)\n\n1. Symptomatic brain metastases (Patients with asymptomatic brain metastases are allowed provided they are clinically stable, receiving no or a stable dose of anticonvulsants without steroid treatment for at least 3 weeks.)\n2. Known leptomeningeal disease\n3. Any prior systemic treatment for metastatic disease, except for one cycle of SoC as described under inclusion criteria\n4. Previous treatment with obrixtamig or any anti-DLL3 compound including T-cell engagers and antibody-drug conjugates",{"count":79,"type":22},75,"INTERVENTIONAL",[82],"PHASE2","This phase II clinical trial evaluates the efficacy, safety and tolerability of Obrixtamig in addition to standard of care chemotherapy (Platinum\u002FEtoposide) in LCNEC.",[85],"Large Cell Neuroendocrine Carcinoma of the Lung",[87,88,89,90],"lung cancer","LCNEC","lung carcinoma","neuroendocrine carcinoma","NOT_YET_RECRUITING","2026-04-27",{"date":94,"type":38},"2026-05-01",{"date":96,"type":22},"2026-07",{"date":98,"type":22},"2032-04",{"name":44,"class":45},{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":106,"targetDuration":55,"studyType":23,"phases":4,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},"100636107","dresden-mds-registry-with-an-accompanying-biomaterial-collection-100636107","NCT07561385","Dresden MDS Registry With an Accompanying Biomaterial Collection","Inclusion Criteria:\n\n* Diagnosis of myelodysplastic syndrome (MDS), MDS\u002FMPN overlap syndrome or evidence of myelodysplastic precursor syndrome, defined as clonal haematopoiesis without cytopenia (clonal haematopoiesis of indeterminate potential, CHIP) or clonal haematopoiesis with cytopenia (clonal cytopenia of undetermined significance, CCUS) in accordance with current WHO criteria\n* Age ≥18 years\n* Submission of a signed consent form for participation in the MDS Registry\n\nExclusion Criteria:\n\n* No exclusion criteria have been established with regard to the registry's primary objective. In particular, patients with comorbidities and those receiving non-curative treatment may be explicitly included in order to provide a realistic picture of actual care practices\n* Inclusion in the registry is excluded in cases where a written consent form is not available or where patients are unable to understand the nature and implications of participating in this registry",{"count":54,"type":22},"A registry for the study of the epidemiology, clinical course, and progression of myelodysplastic neoplasms (MDS), myelodysplastic\u002Fmyeloproliferative neoplasms (MDS\u002FMPN overlap syndromes), and their precursor syndromes (CHIP, CCUS)",[109,110,111,112],"MDS (Myelodysplastic Syndrome)","MDS\u002FMyeloproliferative Neoplasm (MPN) Overlap Syndrome","CHIP","CCUS Clonal Cytopenia of Undetermined Significance","2026-04-24",{"date":94,"type":38},{"date":116,"type":22},"2026-06",{"date":118,"type":22},"2036-06",{"name":44,"class":45},1,{"id":122,"slug":123,"hasResults":12,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":16,"eligibilityCriteria":127,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":145},"100490631","evaluation-and-further-development-of-an-artificial-intelligence-based-algorithm-for-clinical-decision-support-100490631","NCT05668637","Evaluation and Further Development of an Artificial Intelligence-based Algorithm for Clinical Decision Support","Retrospective Use of Patient Treatment Data for the Evaluation and Further Development of an Artificial Intelligence-based Algorithm for Clinical Decision Support in Invasive Mechanical Ventilation of Intensive Care Patients","Inclusion Criteria:\n\n• Subjects who are 18 years or older and receive invasive mechanical ventilation for \\> 4 hours\n\nExclusion Criteria:\n\n• Patients receiving one-lung ventilation",{"count":129,"type":22},318542,"Invasive mechanical ventilation is one of the most important and life-saving therapies in the intensive care unit (ICU). In most severe cases, extracorporeal lung support is initiated when mechanical ventilation is insufficient. However, mechanical ventilation is recognised as potentially harmful, because inappropriate mechanical ventilation settings in ICU patients are associated with organ damage, contributing to disease burden. Studies revealed that mechanical ventilation is often not provided adequately despite clear evidence and guidelines. Variables at the ventilator and extracorporeal lung support device can be set automatically using optimization functions and clinical recommendations, but the handling of experts may still deviate from those settings depending upon the clinical characteristics of individual patients. Artificial intelligence can be used to learn from those deviations as well as the patient's condition in an attempt to improve the combination of settings and accomplish lung support with reduced risk of damage.",[132],"Invasive Mechanical Ventilation",[134,135,136,32],"Mechanical ventilation","ventilator-induced lung injury","ARDS","2026-04-16",{"date":139,"type":38},"2026-04-21",{"date":141,"type":38},"2023-01-01",{"date":143,"type":22},"2026-09-01",{"name":44,"class":45},8,{"id":147,"slug":148,"hasResults":12,"nctId":149,"briefTitle":150,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":152,"targetDuration":154,"studyType":23,"phases":4,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":158,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":164},"100300270","clinical-aml-registry-and-biomaterial-database-of-the-study-alliance-leukemia-sal-100300270","NCT03188874","Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)","Inclusion Criteria:\n\n* AML according to the WHO (World Health Organization) diagnostic criteria, including acute promyelocytic leukemia\n* Age ≥ 18 years. There is no upper age limit.\n* Signed written informed consent\n\nExclusion Criteria:\n\n* there are no exclusion criteria",{"count":153,"type":22},15000,"10 Years","This is a registry study in adult patients with newly diagnosed or refractory\u002Frelapsed acute myeloid leukemia.\n\nInvestigator's sites: 60 sites in Germany.\n\nPrimary objectives:\n\n* Identification of epidemiological data on AML: age, prognostic factors and subgroup distributions. Incidence and age distribution are compared with the data of population-related tumor registry.\n* Evaluation of the most important patient-relevant clinical endpoints (outcomes): relapse-free survival (RFS) \u002F time to relapse (TTR), calculation of cumulative incidence of relapse (CIR) and overall survival (OS)\n* Documentation of treatment strategy",[157],"Acute Myeloid Leukemia (AML)",{"date":139,"type":38},{"date":160,"type":4},"2010-09",{"date":162,"type":22},"2030-09-30",{"name":44,"class":45},60,{"id":166,"slug":167,"hasResults":12,"nctId":168,"briefTitle":169,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":172,"targetDuration":174,"studyType":23,"phases":4,"briefSummary":175,"conditions":176,"keywords":178,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":120},"100459885","development-intraoperative-demonstration-and-visualization-of-surgical-assistance-functions-100459885","NCT05268432","Development, Intraoperative Demonstration and Visualization of Surgical Assistance Functions","IDEMONSTRATE","Inclusion Criteria:\n\n* Indication for surgery using a laparoscopic or open surgical camera, a surgical robot (e.g., DaVinci system), or an intraoperative imaging modality (e.g. sonography, intraoperative CT)\n* Patient understands German\n\nExclusion Criteria:\n\n* Lack of ability to consent",{"count":173,"type":22},40,"90 Days","The aim of the planned study is the development of surgical assistance functions on the basis of clinical routine data and the evaluation of the technical feasibility of an intraoperative demonstration and visualization of such assistance functions in visceral surgery. Furthermore, this trial aims to provide preliminary data on the clinical outcome of such assistance systems.",[177],"Abdominal Surgery",[179,180],"Surgical data science","computer vision","2026-02-06",{"date":183,"type":38},"2026-02-10",{"date":185,"type":38},"2021-05-19",{"date":187,"type":22},"2050-12-31",{"name":44,"class":45},{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":196,"enrollmentInfo":197,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":210,"locationsCount":120},"100525812","incidence-and-clinical-impact-of-serum-hyperamylasemia-poh-after-pancreatectomy-on-postoperative-outcome-and-patient-safety-100525812","NCT06126601","Incidence and Clinical Impact of Serum Hyperamylasemia (POH) After Pancreatectomy on Postoperative Outcome and Patient Safety","HYPPO","Inclusion Criteria:\n\n* All patients undergoing pancreatic resection for malignant and benign disease with or without pancreatic anastomosis\n* Patients aged 18-85 years\n* Willingness to participate as demonstrated by giving a written informed consent.\n\nExclusion Criteria:\n\n* Necrosectomy (endoscopic or open) for primary acute pancreatitis or within laparotomy\n* Age less than 18 years\n* Surgical drainage procedures without pancreatic resection (cystojejunostomy for pancreatic pseudocysts)\n* One-stage total pancreatectomy\n* Missing written consent","85 Years",{"count":198,"type":22},150,"Recent evidence suggests that postoperative hyperamylasemia (POH) is a predictor of morbidity after pancreatectomy. This is based on the assumption that pancreatitis after pancreatectomy (PPAP) is a major trigger for the development of complications and is indicated by hyperamylasemia. Standardized prospective analysis and correlation with other laboratory parameters, hasn't been performed to date.\n\nTherefore the overall study aims are:\n\n* To prospectively evaluate the incidence and assess the clinical value of biochemical changes for the postoperative course.\n* To confirm and improve the definition and classification of postpancreatectomy acute pancreatitis (PPAP) of the International Study Group of Pancreatic Surgery (ISGPS) and to provide knowledge for effective early management of complications.",[201,202,203],"Pancreatectomy","Hyperamylasemia","Pancreatitis, Acute","2026-02-02",{"date":206,"type":38},"2026-02-03",{"date":208,"type":38},"2023-07-18",{"date":96,"type":22},{"name":44,"class":45},{"id":212,"slug":213,"hasResults":12,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":80,"phases":221,"briefSummary":223,"conditions":224,"keywords":226,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":234,"locationsCount":120},"100489380","machine-learning-based-surgical-guidance-system-for-robot-assisted-rectal-surgery-100489380","NCT05652361","Machine Learning-based Surgical Guidance System for Robot-assisted Rectal Surgery","Machine Learning-based Surgical Guidance System for Robot-assisted Rectal Surgery - a First-in-human Interventional Study","CoBot2","Inclusion Criteria:\n\n* Patients with rectal cancer scheduled for robot-assisted rectal resection\n* Intact preoperative urogenital\u002Frectal function\n* Full capability of consent\n\nExclusion Criteria:\n\n* Previous\u002FSecond malignant disease \\\u003C5 years before diagnosis of rectal cancer\n* Previous abdominal surgery, except for laparoscopic appendectomy, laparoscopic cholecystectomy or Cesarean section\n* Pregnant or breastfeeding women\n* Addiction or illness that prevent the person concerned from assessing the nature and scope of the clinical trial and its possible consequences\n* indication that the participant is unlikely to comply with the trial protocoll (e.g. lack of compliance)\n* official or court order for involuntary hospitalization",{"count":220,"type":22},12,[222],"NA","The aim of the study is to evaluate the technical feasibility and applicability of a surgical assistance system based on image recognition algorithms in a first-in-human pilot study. In addition, this study will provide preliminary data on the oncological outcome of the assistance system.",[225],"Rectum Cancer",[227,228],"Robotic Surgery","Total mesorectal excision",{"date":230,"type":38},"2026-02-05",{"date":232,"type":22},"2026-02",{"date":42,"type":22},{"name":44,"class":45},{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":80,"phases":245,"briefSummary":247,"conditions":248,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":120},"100504099","phase-3-pancreatic-head-resection-or-total-pancreatectomy-with-islet-autotransplantation-in-patients-with-periampullary-cancer-and-high-risk-profile-for-the-development-of-postoperative-pancreatic-fistula-100504099","NCT05843877","Pancreatic Head Resection or Total Pancreatectomy With Islet Autotransplantation in Patients With Periampullary Cancer and High Risk Profile for the Development of Postoperative Pancreatic Fistula","Pancreatic Head Resection or Total Pancreatectomy With Islet Autotransplantation (IAtx) in Patients With Periampullary Cancer and High Risk Profile for the Development of Postoperative Pancreatic Fistula (POPF)","XandTX","Inclusion Criteria:\n\n* suspected or confirmed periampullary carcinoma (tumor) and indication for PPPD (pylorus-preserving pancreaticoduodenectomy) or Whipple surgery\n* high-risk profile for the development of a postoperative pancreatic fistula (POPF) after pancreatic head resection: soft pancreas and Pancreatic duct diameter \\\u003C 3 mm (preoperative and intraoperative confirmation)\n* written informed consent of the participant after successful Informed consent\n\nExclusion Criteria:\n\n* patients on whom another procedure is to be performed simultaneously in addition to PPPD or Whipple surgery\n* confirmed other primary tumor\n* previous transplantation of an organ or tissue\n* known infection with HIV (HIV antibodies)\n* positive hepatitis C antibodies, positive hepatitis B surface antigens and hepatitis Bc antibodies\n* insulin-treated diabetes mellitus\n* history of hypersensitivity to any of the drugs used or their ingredients or to drugs with a similar chemical structure\n* concurrent participation in another clinical trial (incl. within the last 4 weeks prior to inclusion).\n* addiction or other medical conditions that do not allow the subject to understand the nature and not be able to appreciate the nature, scope and possible consequences of the trial\n* pregnant or breastfeeding women\n* women of childbearing age, except for women who meet the following criteria:\n\n  1. Post-menopausal (12 months of natural amenorrhea or 6 months of amenorrhea with Serum FSH \\> 40 U\u002Fml)\n  2. Post-operative (6 weeks after bilateral ovariectomy with or without hysterectomy)\n  3. Regular and correct use of a contraceptive method with an failure rate \\\u003C 1% per year\n  4. Sexual abstinence\n  5. Vasectomy of the partner\n* evidence that the patient is unlikely to comply with the protocol",{"count":244,"type":22},32,[246],"PHASE3","The primary objective of this clinical trial is to evaluate whether primary total pancreatectomy with simultaneous islet autotransplantation compared with pancreatic head resection (alone) can reduce perioperative morbidity and time to initiation of adjuvant therapy in patients with a high-risk constellation for pancreatic fistulas.",[249,250],"Periampullary Cancer","Postoperative Pancreatic Fistula","2026-01-28",{"date":253,"type":38},"2026-01-30",{"date":255,"type":38},"2025-01-28",{"date":257,"type":22},"2028-01",{"name":44,"class":45},{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":265,"eligibilityCriteria":266,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":267,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":269,"conditions":270,"keywords":275,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":46},"100604336","quality-of-life-and-medical-care-of-long-term-sarcoma-survivors-in-germany-prosa-100604336","NCT07148193","Quality of Life and Medical Care of Long-term Sarcoma Survivors in Germany (PROSa+)","Understanding Long-Term Sarcoma Survivorship: Risk Profiles, Outcomes and Unmet Needs - A Joint Project of Research, Sarcoma Centres and Patient Experts (PROSa+)","PROSa+","Inclusion Criteria:\n\n* Diagnosis of sarcoma according to the International Classification of Diseases for Oncology (ICD-O) and World Health Organization (WHO) classification, including soft tissue sarcoma, bone sarcoma, and GIST\n* At least 5 years since initial sarcoma diagnosis\n* With or without active disease\n* Age ≥18 years at the time of study participation\n\nExclusion Criteria:\n\n* Diagnosis of Desmoid tumors\n* Inability to complete a structured questionnaire (e.g., due to insufficient German language skills, cognitive impairment, dementia)",{"count":268,"type":22},1600,"The study PROSa+ aims to assess patient-reported outcomes (PROs), patient-reported experiences (PREs), and the socioeconomic situation of long-term sarcoma survivors (≥ 5 years post-diagnosis, with or without active disease) in Germany. The mixed-methods research design includes a multicenter observational study with a cross-sectional questionnaire survey involving 1,600 participants (paper, online), qualitative interviews with up to 60 participants, and longitudinal analyses combining data from existing sarcoma registries and the previous PROSa study conducted between 2017 and 2020.",[271,272,273,274],"Sarcoma","Survivorship","Quality of Life (QOL)","Medical Care",[271,276,277,278,274,279,280,281,282],"Neoplasms","Patient-Reported Outcomes","Patient-Reported Experiences","Quality of Life","Unmet Health Needs","Oncology","Psycho-Oncology","2025-12-01",{"date":285,"type":38},"2025-12-08",{"date":287,"type":38},"2025-11-28",{"date":289,"type":22},"2027-09",{"name":44,"class":45},{"id":292,"slug":293,"hasResults":12,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":297,"eligibilityCriteria":298,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":80,"phases":301,"briefSummary":302,"conditions":303,"keywords":305,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":321},"100316219","de-escalation-of-adjuvant-radio-chemo-therapy-for-hpv-positive-head-neck-squamous-cell-carcinomas-100316219","NCT03396718","De-escalation of Adjuvant Radio (Chemo) Therapy for HPV-positive Head-neck Squamous Cell Carcinomas","De-escalation of Adjuvant Radio (Chemo) Therapy for HPV-positive Head and Neck Squamous Cell Carcinomas: A Phase I Study to Reduce Late Toxicity","DELPHI","Inclusion Criteria:\n\n* Condition after surgical removal of a squamous cell carcinoma of the oropharynx and adequate lymph node dissection\n* Indication for adjuvant radiotherapy or radiochemotherapy in the interdisciplinary tumor board\n* Good general state (ECOG performance status 0 or 1)\n* Adequate compliance to ensure closely follow-up\n* Patient's consent and written consent\n* Neck dissection of at least the tumor bearing side\n\nAdditional Inclusion Criteria Arm intermediate risk (at least one of the criteria must be fulfilled):\n\n* pT3 and R0 and \u002F or\n* histologically confirmed involvement of lymph nodes (n = 1-3) and no extracapsular extension of the lymph node metastasis\n\nAdditional Inclusion Criteria Arm high risk (at least one of the criteria must be fulfilled):\n\n* residual tumor (R1 status) and \u002F or\n* pathologic stage T4 (pT4) status and \u002F or\n* more than 3 infected lymph nodes and \u002F or\n* extracapsular extension of at least one lymph node metastasis\n\nExclusion Criteria:\n\n* Patients with a cumulative nicotine abuse \\> 30 packyears. These patients are not included in the intervention arms, but are always included in the observation arms (regardless of HPV status).\n* radiologically presumed or histologically confirmed distant metastasis\n* R2 resection or macroscopically visible residual tumor after surgery\n* no neck dissection\n* interval between last operation and planned irradiation start \\> 7 weeks\n* contraindication against a guideline-appropriate adjuvant radiation or radiochemotherapy according to the clinical risk constellation\n* tumor disease in the last five years before the beginning of the study (except basaliomas of the skin, in-situ carcinoma of the cervix uteri or breast, or tumors with similar prognosis which are considered to be very likely to be cured)\n* malignant tumor disease in the head and neck region, regardless of interval and prognosis\n* Pre-irradiation with risk of dose overlap\n* participation in another clinical trial if further experimental therapy is necessary or the treatments\u002F protocols are mutually exclusive (e.g. altered chemotherapy, additional consolidation chemotherapy). Allowed is the additional participation in observation studies or supportive therapy studies.\n* diseases or conditions which do not allow the person concerned to assess the nature and scope and possible consequences of the clinical trial\n* pregnant or lactating women\n* evidence that the participant is not expected to comply with the study protocol (e.g. lack of cooperation)\n* missing written consent",{"count":300,"type":22},304,[222],"In patients with squamous cell carcinoma of the oral cavity, the oropharynx and larynx with local advanced tumors (pathologic stage T3 = pT3) and or lymph node involvement (pN+) postoperative radio - or radiochemotherapy is the standard of care. Postoperative radiochemotherapy is indicated in patients with multiple lymph node metastasis, lymph node metastasis with extracapsular spread and \u002F or residual tumor (R1-Status) after resection. Oropharyngeal cancer caused by HPV (human papillomavirus 16) is a distinct subgroup with a known sensitivity to radiotherapy (RTx) or radiochemotherapy (RCTx). Additionally a superior outcome after R(C)Tx over HPV negative patients was shown for patients treated with primary or adjuvant RCTx. To date it is unknown if the total dose of the radiotherapy can be safely reduced with the aim to decrease the therapy associated late effects.\n\nPatients with a HPV associated carcinoma that take part in the study will be treated with a reduced radiotherapy dose, chemotherapy will be prescribed based on clinical factors (number of affected lymph node, presence of extracapsular spread or residual tumor). Radiation dose will be reduced in two steps.",[304],"Head-and-neck Squamous Cell Carcinoma",[306,307,308,309,310,311,312],"Head and neck cancer","Oropharyngeal cancer","postoperative","radiotherapy","radiochemotherapy","de-intensification","HPV","2025-09-16",{"date":315,"type":38},"2025-09-22",{"date":317,"type":38},"2018-11-29",{"date":319,"type":22},"2032-11-30",{"name":44,"class":45},10,{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":330,"targetDuration":4,"studyType":80,"phases":332,"briefSummary":333,"conditions":334,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":344},"100594928","phase-2-evaluation-of-treosulfan-versus-melphalan-conditioning-followed-by-ptcy-in-patients-with-aml-and-mds-undergoing-allogeneic-transplantation-100594928","NCT07025824","Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation","Randomized Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation","RELEVANT","Main Inclusion Criteria:\n\n1. Informed consent signed by the patient capable of giving\n2. Patient scheduled for allogeneic transplantation within the next 3 weeks\n3. Age ≥ 18 years\n4. AML or MDS according to WHO with indication for allogeneic HCT:\n\n   1. AML in first or second complete remission (CR) or complete remission with incomplete hematologic recovery (CRi\u002FCRh) or morphologic leukemia-free state (MLFS)\n   2. MDS according to WHO\n5. Increased risk for treatment-related toxicity by myeloablative conditioning according to at least one of the following criteria:\n\n   1. Patients aged ≥ 50 years at transplant and\u002For\n   2. HCT-CI \\> 2 and\u002For\n   3. AML or MDS scheduled for 2nd allogeneic HCT from different donor with minimum of 12 months after 1st allogeneic HCT\n6. Availability of a suitable donor:\n\n   1. Matched sibling donor (MSD) or\n   2. matched unrelated donor (MUD, 10\u002F10 HLA) or\n   3. mismatched unrelated donor (MMUD, single allele or antigen mismatch at HLA-A, -B, -C, or -DRB1 and no concurrent -DQB1 mismatch (9\u002F10) shown by confirmatory typing) or\n   4. haploidentical family donor\n7. Planned GvHD prophylaxis with standard PTCy (with 50mg\u002Fkg body weight on days +3 and +4)\n8. No history of cardiac disease that preclude allogeneic HCT and absence of active symptoms, otherwise, documented left ventricular ejection fraction\n\n   * 40 %.\n9. No need for supplementary oxygen on day of randomization\n\nMain Exclusion Criteria:\n\n1. Patients with acute promyelocytic leukemia with t(15;17)(q22;q12)\n2. Patients with graft failure after previous allogeneic HCT\n3. Patients with scheduled 2nd allogeneic HCT within 12 months after 1st allogeneic HCT\n4. Pretreatment with either melphalan or treosulfan within the last 12 months prior to randomization\n5. Planned TBI as part of conditioning\n6. Severe organ dysfunction defined by either one of the following criteria:\n\n   1. Serum bilirubin \\> 1.5 × ULN (if not considered Gilbert-syndrome) or\n   2. ALAT or ASAT \\> 5 × ULN\n7. Uncontrolled infection at the time of randomization.\n8. Active viral hepatitis unless serology demonstrates clearance of infection. Occult or prior hepatitis B virus (HBV) infection, defined as negative hepatitis B surface antigen and positive total hepatitis core antibodies, may be included if HBV DNA is undetectable, provided that patients are willing to undergo monthly DNA testing. Patients who have protective titers of hepatitis B surface antibody after vaccination or prior cured hepatitis B are eligible. Patients for hepatitis C virus (HCV) antibody are eligible provided PCR if negative for HCV RNA.\n9. Pregnant or breastfeeding women",{"count":331,"type":22},220,[82],"The aim of this study is to compare the effectiveness and tolerability of two conditioning chemotherapies prior to allogeneic stem cell transplantation.\n\nThe following will also be investigated:\n\n* Survival\n* Remission and Relapse rate\n* Engraftment or graft failure\n* Graft versus Host Disease (GvHD)",[335,109],"AML - Acute Myeloid Leukemia","2025-09-02",{"date":338,"type":38},"2025-09-03",{"date":340,"type":22},"2025-09",{"date":342,"type":22},"2028-12",{"name":44,"class":45},4,{"id":346,"slug":347,"hasResults":12,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":351,"eligibilityCriteria":352,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":353,"enrollmentInfo":354,"targetDuration":4,"studyType":80,"phases":356,"briefSummary":358,"conditions":359,"keywords":361,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":374},"100392076","phase-1-combination-of-midostaurin-and-gemtuzumab-ozogamicin-in-first-line-standard-therapy-for-acute-myeloid-leukemia-mosaic-100392076","NCT04385290","Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)","MidOStaurin + Gemtuzumab OzogAmIcin Combination in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)","MOSAIC","Inclusion Criteria:\n\n* Written informed consent\n* Newly diagnosed AML according to the criteria of the World Health Organisation plus the following molecular or cytogenetic specifications:\n\n  * Phase I Trial - MODULE:\n\n    * t(8;21)\u002FRUNX1-RUNX1T1 or\n    * inv(16) or t(16;16)\u002FCBFB-MYH11 or\n    * FLT3-ITD or\n    * FLT3-tyrosine kinase domain (FLT3-TKD)\n  * Phase II Trial - MAGNOLIA\n\n    * t(8;21)\u002FRUNX1-RUNX1T1 or\n    * inv(16) or t(16;16)\u002FCBFB-MYH11\n  * Phase II Trial - MAGMA\n\n    * FLT3-ITD or\n    * FLT3-TKD\n    * Absence of mutations in CBF genes (i.e. t(8;21)\u002FRUNX1-RUNX1T1 or inv(16) or t(16;16)\u002FCBFB-MYH11)\n* Male and female patients aged\n\n  * 18 - ≤ 75 years in Phase I Trial - MODULE\n  * 18 - ≤ 70 years in Phase II Trials - MAGMA and MAGNOLIA\n* Eastern Cooperative Oncology Group (ECOG) Score of 0-2\n* Life expectancy \\> 14 days\n* Adequate hepatic and renal function\n\n  * alanine aminotransferase \u002F aspartate transaminase ≤ 2.5 x ULN\n  * Bilirubin \\\u003C 2 x upper limits of normal\n  * Creatinine \\\u003C 1.5 x upper limits of normal or Creatinine clearance \\> 40 ml\u002Fmin\n* White blood cell count \\\u003C 30 × 10\\^9\u002FL. Note: Hydroxyurea and\u002For a dose of 100-200 mg\u002Fm\\^2 cytarabine per day for up to 3 days (for emergency use for clinical stabilization) is permitted to meet this criterion.\n\nExclusion Criteria (all study parts):\n\n* Previous antineoplastic treatment for AML other than hydroxyurea and\u002For cytarabine for emergency use (100-200 mg\u002Fm\\^2 per day on maximal 3 days)\n* Previous treatment with anthracyclines\n* central nervous system involvement\n* Isolated extramedullary AML\n* Uncontrolled infection\n* AML after antecedent myelodysplasia (MDS) with prior cytotoxic treatment (e.g., azacytidine or decitabine)\n* Any investigational agent within 30 days or 5 half-lives, whichever is greater, prior to day 1. An investigational agent is defined as an agent with no approved medical use in adults or in pediatric patients\n* Prior treatment with a FLT3 inhibitor (e.g., midostaurin, quizartinib, sorafenib)\n* Strong CYP3A4\u002F5 enzyme inducing drugs unless they can be discontinued or replaced prior to enrollment\n* Any other known disease or concurrent severe and\u002For uncontrolled medical condition (e.g., cardiovascular disease including congestive heart failure or active uncontrolled infection) that could compromise participation in the study\n* Impairment of gastrointestinal (GI) function or GI disease that might alter significantly the absorption of midostaurin\n* Confirmed diagnosis of HIV infection,\n* Active viral hepatitis unless serology demonstrates clearance of infection. Occult or prior hepatitis B virus (HBV) infection, defined as negative hepatitis B surface antigen and positive total hepatitis core antibodies, may be included if HBV DNA is undetectable, provided that patients are willing to undergo monthly DNA testing. Patients who have protective titers of hepatitis B surface antibody after vaccination or prior cured hepatitis B are eligible. Patients for hepatitis C virus (HCV) antibody are eligible provided PCR is negative for HCV RNA.\n* Cardiovascular abnormalities, including any of the following:\n\n  * History of myocardial infarction, angina pectoris, Coronary Artery Bypass Grafting within 6 months prior to starting study treatment\n  * Clinically uncontrolled cardiac arrhythmias (e.g., ventricular tachycardia), complete left bundle branch block, high-grade atrioventricular block (e.g., bifascicular block, Mobitz type II and third degree atrioventricular block)\n  * Uncontrolled congestive heart failure\n  * Left ventricular ejection fraction of \\\u003C 50%\n  * Poorly controlled arterial hypertension\n* Pregnant or nursing (lactating) women\n* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they fulfill at least one of the following criteria:\n\n  * Post-menopausal (12 months of natural amenorrhea or 6 months of amenorrhea with serum follicule stimulating hormone \\> 40 U\u002Fml)\n  * Postoperative (i.e. 6 weeks) after bilateral ovariectomy with or without hysterectomy\n  * Women of childbearing potential must have a negative serum pregnancy test performed within 7 days before the first dose of study drug\n  * Continuous and correct application of a contraception method with a Pearl Index of \\\u003C 1% (e.g. implants, depots, oral contraceptives, intrauterine device) from initial study drug administration until at least 7 months after the last dose of gemtuzumab ozogamicin and at least 4 months after the last dose of midostaurin, whichever period is longer. A hormonal contraception method must always be combined with a barrier method (e.g. condom)\n  * Sexual abstinence\n  * Vasectomy of the sexual partner\n* Sexually active males unless they use a condom during intercourse while taking the drug during treatment, and for at least 4 months after stopping treatment and should not father a child in this period. A condom is required to be used also by vasectomized men as well as during intercourse with a male partner in order to prevent delivery of the drug via semen\n* Unwillingness or inability to comply with the protocol\n* Known hypersensitivity to midostaurin, GO, cytarabine or daunorubicin or to any of the excipients of midostaurin, GO, cytarabine or daunorubicin.","75 Years",{"count":355,"type":22},214,[357,82],"PHASE1","This phase I\u002FII clinical trial evaluates the safety and efficacy of the combined administration of midostaurin and gemtuzumab ozogamicin in the frame of first-line standard chemotherapy in newly diagnosed acute myeloid leukemia (AML) patients displaying a cytogenetic aberration or fusion transcript in the core-binding factor (CBF) genes or FMS-like tyrosine Kinase 3 (FLT3) mutation.",[360],"Acute Myeloid Leukemia",[362,363,364,365,366],"AML","FLT3 mutation","CBF","midostaurin","gemtuzumab ozogamicin",{"date":368,"type":38},"2025-09-08",{"date":370,"type":38},"2020-09-04",{"date":372,"type":22},"2028-04",{"name":44,"class":45},21,{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":379,"acronym":380,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":383,"conditions":384,"keywords":388,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":400,"completionDateStruct":401,"leadSponsor":403,"locationsCount":404},"100604521","immune-marker-platform-for-patients-with-advanced-lung-cancer-100604521","NCT07150598","Immune-Marker Platform for Patients With Advanced Lung Cancer","IMPALUX","Inclusion Criteria:\n\nFor all:\n\n* Written informed consent of the patient\n* Consent of participation in the national Network for Genomic Medicine in Lung Cancer (nNGM)\n* Advanced lung cancer with non-curative treatment option (NSCLC)\n* No targetable driver mutation detected, defined as no targetable drive mutation in ALK, EGFR, BRAF, HER2, MET, NTRK, RET, ROS1\n* PD-L1 expression on tumor cells (TPS \\\u003C 50%)\n\nCohort A:\n\n* Previously untreated NSCLC without curative treatment options\n* Sufficient pre-treatment tumor material available for the planned analyses or consenting and able to undergo additional pretreatment biopsy\n* Scheduled to undergo immune(chemo)therapy\n* Willing and able to undergo re-biopsy 6 weeks after start of immune(chemo)therapy\n\nCohort B:\n\n* Any line of progression after firstline immune(chemo)therapy\n* Sufficient tumor material obtained after progression on most recent line of treatment available or willing and able to undergo re-biopsy prior to next line treatment\n\nExclusion Criteria:\n\n* Any condition representing an unjustified risk for obtaining an additional biopsy sample (if needed) in the view of the investigator\n* Incapability of understanding the purpose and possible consequences of the trial\n* Substance abuse, medical, psychological or social conditions that may interfere with the subject's cooperation with the requirements of the trial or evaluation of the study results",{"count":54,"type":22},"The goal of this observational study is to better understand how the immune system and certain tumor markers are linked to treatment response in patients with advanced non-small cell lung cancer (NSCLC) who receive immunochemotherapy.\n\nThe investigators aim to answer the following questions:\n\n* Can the investigators successfully analyze immune markers and gene activity from small tumor samples (biopsies)?\n* Are these markers connected to how well patients respond to immunochemotherapy and how their disease progresses?\n\nWhat will participants do?\n\n* Provide tumor tissue samples (biopsies) at key points: before treatment, about 6 weeks after starting immunochemotherapy, and if the cancer grows or treatment changes.\n* Allow their tumor samples to be analyzed in the lab using advanced techniques to measure immune and genetic markers.\n* Share clinical information (such as treatment response and disease progression) so investigators can study how it relates to these markers.\n\nThis study does not test a new drug or treatment.",[385,386,387],"NSCLC (Advanced Non-small Cell Lung Cancer)","NSCLC Stage IIIB~IV","NSCLC Non-small Cell Lung Cancer",[389,390,391,392,393,394,395,396,397],"Non-Small Cell Lung Cancer","NSCLC","Immunochemotherapy","Multiplex Immunofluorescence","3'-RNA Sequencing","Prospective Observational Study","Tumor Microenvironment","Therapy Response","Precision Oncology","2025-09-01",{"date":368,"type":38},{"date":398,"type":22},{"date":402,"type":22},"2027-06-01",{"name":44,"class":45},2,{"id":406,"slug":407,"hasResults":12,"nctId":408,"briefTitle":409,"officialTitle":410,"acronym":411,"eligibilityCriteria":412,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":413,"targetDuration":4,"studyType":80,"phases":415,"briefSummary":416,"conditions":417,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":120},"100503564","phase-1-a-phase-i-trial-to-establish-the-safety-and-maximum-tolerated-dose-of-high-affinity-autologous-bcma-targeting-chimeric-antigen-receptor-car-t-cells-in-patients-with-relapsed-and-refractory-b-cell-malignancies-100503564","NCT05836896","A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies","A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting CAR T-cells in Patients With Relapsed and Refractory B-cell Malignancies","CARLOTTA01","Inclusion Criteria:\n\n* Male or female patients aged ≥ 18 years\n* Written informed consent of the subject\n* Able and willing to adhere to the trial protocol\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Either Multiple Myeloma (MM):\n\n  1. relapsed or refractory disease after at least 2 lines of treatment including an Immunomodulatory drug, a proteasome inhibitor and an anti-cluster of differentiation 38 antibody or anti-cluster of differentiation 319 (SLAMF7; Elotuzumab) antibody AND\n  2. not eligible for treatment with other regimen available according to local standard of care and known to confer clinical benefit according to the investigator's discretion, prior treatment with other BCMA-targeting immunotherapies (including T-cell engaging antibodies, CAR T-cells and antibody-drug immuno-conjugates) is allowed AND\n  3. measurable disease defined by serum M-Protein ≥ 10 g\u002Fl OR urine M-Protein ≥ 200 mg\u002F24h OR serum free light chain \\> 100 mg\u002Fl of involved free light chain and abnormal serum free light chain ratio\n\n     OR\n\n     Diffuse large B-cell lymphoma (DLBCL):\n  4. Relapsed after or refractory to standard curative therapy (such as R-CHOP) and refractory to at least one course of standard salvage chemotherapy OR\n  5. Relapsed within one year after high-dose chemotherapy and autologous stem cell support OR\n  6. Relapsed after allogeneic stem-cell transplantation or approved anti-cluster of differentiation 19 CAR T-cell therapies.\n\n     AND (applicable to all DLBCL patients)\n  7. Not be eligible for treatment with other regimen available according to local standard of care and known to confer clinical benefit. This includes but is not limited to anti-cluster of differentiation 19 directed CAR T-cell therapies with approved constructs AND (applicable to all DLBCL patients)\n  8. Measurable disease according to Lugano criteria\n* Adequate organ function defined as:\n\n  1. Neutrophils ≥ 0.5 Gpt\u002Fl and Platelets ≥ 50 Gpt\u002Fl (unless due to subtotal infiltration of the bone marrow by underlying malignancy)\n  2. Lymphocytes ≥ 0.1 Gpt\u002Fl\n  3. Alaninaminotransferase and Asparataminotransferase ≤ 3.0x Upper limit of normal\n  4. Bilirubin ≤ 1.5x Upper limit of normal\n  5. Creatinine ≤ 1.5x Upper limit of normal\n  6. Adequate cardiac function i.e. left ventricular ejection fraction ≥ 50%, no major valve abnormalities or dyskinesias\n* A female of childbearing potential\\* may be enrolled providing she has a negative pregnancy test at screening and is routinely using a highly effective method of birth control (pearl index of ≤ 1 required) resulting in a low failure rate (e.g. hormonal contraception, intrauterine device, total sexual abstinence or sterilization). Male patients must also prac-tice a highly effective method of birth control and should not father a child at least until 12 months after infusion of CAR T-cells\n\nExclusion Criteria:\n\n* Any Central nervous system (CNS)-involvement by underlying disease\n* History of seizure or cerebrovascular ischemia \u002F hemorrhage within the last 12 months\n* History of any autoimmune Central nervous system disease (e.g. multiple sclerosis, amyotrophic lateral sclerosis, optic neuritis)\n* Ongoing neurologic conditions that in the opinion of the investigator might increase the risk for neurotoxicity or impair the assessment of CAR-associated neurotoxicity\n* Inadequate pulmonary function (i.e. need for continuous oxygen support)\n* Patients on hemodialysis\n* Any contraindications to Fludarabine and\u002For Cyclophosphamide as given in the Summary of product characteristics\n* Any other active malignancy requiring active treatment or interfering with the assessment of primary or secondary trial endpoints, adjuvant hormonal therapy is allowed\n* Positivity for anti-human immunodeficiency virus (HIV) immunoglobulin\n* Active or chronic infectious hepatitis B (HBV) and C (HCV) virus unless serology demonstrates clearance of infection (i.e. Polymerase chain reaction undetectable viral load for hepatitis)\n* Active infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) or history of SARS-CoV2 infection within the past 3 months or active long coronavirus disease (COVID) syndrome\n* Uncontrolled bacterial, viral or fungal infections defined as infections needing in-patient and\u002For i.v. antimicrobial treatment\\*\n* Active Graft versus Host Disease defined as active symptoms of graft-versus-host disease or ongoing immunosuppressive treatment or prophylaxis within the last 30 days prior to application of MDC-CAR-BCMA001\n* Psychologic disorders, drug abuse or any other condition which might significantly impair a patient's ability to comply with the trial protocol\n* Patients who are expected to deteriorate during the time needed for manufacturing MDC-CAR-BCMA001 in spite of bridging therapy in the opinion of the investigator including\n* Any condition requiring systemic treatment with immunosuppressive drugs (including but not limited to steroids exceeding 20 mg Prednisolone per day)\n* Any antineoplastic treatment within 7 days prior to leukapheresis or within 2 weeks or 5 half-lives (whatever is shorter) of the start of lymphodepleting chemotherapy (palliative radiotherapy to lesions not essential for response assessment is allowed without a minimal washout period)\n* Any investigational therapy within 4 weeks or 5 half-lives (whatever is shorter) prior to apheresis or the start of lymphodepleting chemotherapy\n* History of allergic reactions to any drug or its ingredients \u002F impurities foreseen to be given as part of this trial according to the protocol\\*\n* Receipt of live vaccines within 2 weeks prior to leukapheresis and start of lymphodepleting chemotherapy\n* Pregnant or breastfeeding women. Breastfeeding has to be discontinued before onset of and during treatment and should be discontinued for at least 3 months after end of treatment.\n* Women of childbearing potential, except women who meet the following criteria:\n\n  1. post-menopausal (12 months natural amenorrhoea or 6 months amenorrhoea with serum Follicle stimulating hormone \\> 40 U\u002Fml)\n  2. postoperative (6 weeks after bilateral ovariectomy with or without hysterectomy)\n  3. regular and correct use of a contraceptive method with an Pearl Index \\\u003C 1% per year\n  4. sexual abstinence\n  5. Vasectomy of the partner\n* Hypersensitivity known from medical history to one of the drugs used or their ingredients or to drugs with a similar chemical structure\n* Simultaneous participation in another interventional clinical trial (including within the last 4 weeks before inclusion)\n* Addictions or other illnesses that do not allow the person concerned to assess the nature and extent of the clinical trial and its possible consequences\n* Indications that the subject is unlikely to adhere to the protocol (e.g., lack of compliance).",{"count":414,"type":22},16,[357],"The purpose of this phase I study is to determine whether MDC-CAR-BCMA001 (BCMA directed CAR T-cells) is safe and tolerable in the treatment of relapsed and refractory B-cell malignancies",[276,418,419,420,421],"Relapsed Diffuse Large B-cell Lymphoma (DLBCL)","Refractory Diffuse Large B-cell Lymphoma (DLBCL)","Multiple Myeloma, Refractory","Multiple Myeloma in Relapse","2025-08-22",{"date":424,"type":38},"2025-08-24",{"date":426,"type":38},"2024-02-15",{"date":428,"type":22},"2027-06",{"name":44,"class":45},{"id":431,"slug":432,"hasResults":12,"nctId":433,"briefTitle":434,"officialTitle":435,"acronym":436,"eligibilityCriteria":437,"healthyVolunteers":12,"sex":18,"minAge":438,"maxAge":4,"enrollmentInfo":439,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":441,"conditions":442,"keywords":445,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":480,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":486},"100159371","compera--compera-kids-100159371","NCT01347216","COMPERA \u002F COMPERA-KIDS","Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension","COMPERA","Inclusion Criteria:\n\n* All age groups (amendment dated 1 June 2013)\n* Written informed consent\n* Pulmonary hypertension (PH) of either\n\n  * PAH: idiopathic form (IPAH) or\n  * PAH associated with connective tissue diseases (PAH-CTD), with congenital heart defects (PAH-CHD), with HIV infection (PAH-HIV), or the portopulmonary form\n  * Chronic thromboembolic PH (CTEPH)\n  * PH in left heart diseases (with isolated diastolic dysfunction; with systolic dysfunction, other)\n  * PH in pulmonary disease (chronic obstructive pulmonary disease; interstitial fibrosis, etc.)\n  * \"Relative PH\" in CHD after cavopulmonary anastomosis or Fontan-type surgery, even without the classical pulmonary pressure criteria of PH.\n* Newly initiated (i.e. a maximum of 3 months before documentation for the first time) therapy with endothelin receptor antagonists (ERA), phoshodiesterase-5 (PDE-5) inhibitors, soluble guanylate cyclase (sGC) stimulators or prostacyclins in mono- or combination therapy.\n\nExceptions: PAH-CHD patients can be included on maintenance or newly initiated PAH therapy (3-month rule dose not apply).\n\nPAH-CHD patients with severe pulmonary vascular disease (e.g. Eisenmenger physiology) irrespective of treatment with any PAH drugs are eligible for inclusion, too.\n\nExclusion Criteria:\n\n* Patients on maintenance therapy, i.e. previous treatment with any ERA\u002F PDE-5 inhibitor\u002Fprostacyclin\u002FsGC stimulator drug longer than 3 months before documentation for the first time (exception: PAH-CHD patients).","1 Week",{"count":440,"type":22},14000,"In view of the manifold options for mono- and combination therapy that have now emerged for patients with pulmonary (arterial) hypertension (PH\u002FPAH), controlled clinical trials can only provide part of the information needed for optimal management. In order to gather adequate data on PAH\u002FPH treatment in routine clinical care, the ongoing COMPERA registry prospectively documents consecutive patients with newly initiated treatment of PAH\u002FPAH since May 2007. The internet-based registry fulfills high quality standards through several measures (planned minimum centre contribution of at least 10 patients per year, automated plausibility checks of data at entry, queries, monitoring with source data verification in \\>50% of participating centers). It can be applied, among further purposes, for quality assurance: individual centers can confidentially compare their results with the combined outcome of other centers and the recommendations from guidelines. It is expected that the register contributes to optimization of specific drug therapy for PAH and PH.\n\nSince July 2013, also children of any age can be documented (COMPERA-KIDS).",[443,444],"Pulmonary Arterial Hypertension (PAH)","Pulmonary Hypertension (PH)",[446,447,448,449,450,451,452,453,454,455,456,457,458,459,460,461,462,463,464,465,466,467,468,469,470,471,472,473,474,475,476,477,478,479],"Drug treatment","Treatment pathways","Clinical routine","Registry","Treatment outcomes","Endothelin receptor antagonist","Phosphodiesterase-V inhibitor","Prostanoid","Sildenafil","Bosentan","Macitentan","Sitaxentan","Ambrisentan","Imatinib","Epoprostenol","Treprostinil","Iloprost","Infusion pump","Riociguat","soluble guanylate cyclase stimulator","Quality of life","Patient-related outcomes","Economic model","Adverse event","Safety","Combination therapy","Internet","Europe","Eisenmenger","Adults","Children","Selexipag","Baltic states","Risk",{"date":424,"type":38},{"date":482,"type":38},"2007-07-01",{"date":484,"type":22},"2026-12-31",{"name":44,"class":45},7,{"id":488,"slug":489,"hasResults":12,"nctId":490,"briefTitle":491,"officialTitle":492,"acronym":493,"eligibilityCriteria":494,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":495,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":497,"conditions":498,"keywords":500,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":505,"lastUpdatePostDateStruct":506,"startDateStruct":508,"completionDateStruct":510,"leadSponsor":512,"locationsCount":120},"100588161","replication-of-the-heads-up-atopic-dermatitis-trial-with-registry-data-100588161","NCT06937788","Replication of the Heads Up Atopic Dermatitis Trial With Registry Data","Pragmatic Replication of the Heads Up Head-to-head Study of Upadacitinib and Dupilumab With TREATgermany Registry Data","Re-HU-TREAT","Inclusion Criteria:\n\n* Chronic AD with onset of symptoms at least 3 years prior to baseline\n* Meets UK working party criteria\n* EASI score ≥ 16\n* ≥ 10% body surface area (BSA) of AD involvement at baseline (\"therapy start\") visit\n\nExclusion Criteria:\n\n* contraindications according to upadacitinib or dupilumab labeling",{"count":496,"type":22},240,"The goal is the replication of the primary outcome (EASI 75 at week 16) of the Heads Up trial (Blauvelt, A, Teixeira, H, Simpson, E et al (2021) doi:10.1001\u002Fjamadermatol.2021.3023) and the evaluation of the patient reported outcomes (POEM, DLQI and RECAP) in a head-to-head comparison of upadacitinib versus dupilumab treatment in moderate-to-severe atopic dermatitis (AD).",[499],"Atopic Dermatitis",[501,502,503,504],"observational","target trial emulation","dupilumab","upadacitinib","2025-08-20",{"date":507,"type":38},"2025-08-21",{"date":509,"type":38},"2021-08-02",{"date":511,"type":22},"2025-12-31",{"name":44,"class":45},{"id":514,"slug":515,"hasResults":12,"nctId":516,"briefTitle":517,"officialTitle":518,"acronym":519,"eligibilityCriteria":520,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":521,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":523,"conditions":524,"keywords":526,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":537,"completionDateStruct":539,"leadSponsor":540,"locationsCount":120},"100453241","evaluation-of-a-flexible-and-integrative-psychiatric-care-model-at-the-pfalzklinikum-evapfalz-100453241","NCT05181982","Evaluation of a Flexible and Integrative Psychiatric Care Model at the Pfalzklinikum (EVA_Pfalz)","Wissenschaftliche Evaluation Des Modellvorhabens (§ 64b SGB V) am Pfalzklinikum (EVA_Pfalz)","EVA_Pfalz","Inclusion Criteria:\n\n* treatment at the Pfalzklinikum or control hospital after 01.01.2020 (date included) and before 31.12.2023 (date included) with one of the following diagnoses as main diagnosis (ICD-10: F00, F01, F02, F03, F07, F10, F20-29, F30-39, F43, F45, F40-48, F50, F60.31, F70-79, F84, F90-F98, B22 \\& F02.8, G20.0 \\& F02.3, G30.0 \\& F00.0, G30.1 \\& F00.1) at the department of psychiatry (FA 29xx), department of child and adolescent psychiatry (F30xx) or department of psychosomatic\u002Fpsychotherapy (FA31xx)\n* being insured with any of the participating SHI funds\n\nExclusion Criteria:\n\n* less than one year follow-up data available\n* non-permanent residence in Germany during observation period",{"count":522,"type":22},10000,"This study is an evaluation of the flexible and integrative psychiatric care model (according to § 64b of the German Social Code Book V (SGB V)) (FIT) at the Pfalzklinikum. The central concern of this evaluation is to answer the question whether the FIT model offer advantages over standard care. The orientation of model care is a more cross-sectoral provision of services through more flexible treatment intensities.",[525],"Mental Health Care",[527,528,529,530,531,532,533,534],"Cross-sectoral Treatment","Flexible and Integrated Treatment","Global Treatment Budget","FIT","Psychiatry","Evaluation","Claims data","Cohort study","2025-08-19",{"date":424,"type":38},{"date":538,"type":38},"2022-09-30",{"date":96,"type":22},{"name":44,"class":45},{"id":542,"slug":543,"hasResults":12,"nctId":544,"briefTitle":545,"officialTitle":546,"acronym":547,"eligibilityCriteria":548,"healthyVolunteers":549,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":550,"targetDuration":4,"studyType":80,"phases":552,"briefSummary":553,"conditions":554,"keywords":560,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":563,"lastUpdatePostDateStruct":564,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":344},"100540464","assessment-of-liver-diseases-using-a-deep-learning-approach-based-on-ultrasound-rf-data-100540464","NCT06317181","Assessment of Liver Diseases Using a Deep-Learning Approach Based on Ultrasound RF-Data","Acquisition and Frequency Spectroscopic Evaluation of Broadband Clinical Ultrasound Raw Data for Liver Cirrhosis and Focal Pathologies Using Neural Networks for Tissue and Pathology Differentiation","LivSPECTRUS","Inclusion Criteria:\n\n* scheduled for an ultrasound investigation by an independent physician\n* signed declaration of consent\n\nExclusion Criteria:\n\n* smaller interventions in the same liver during the last 2 Week (for example liver biopsy)\n* contrast enhanced ultrasound less than a day ago\n* major intervention at the liver (for example partial resection)",true,{"count":551,"type":22},200,[222],"The goal of this clinical trial is to test the performance of neuronal networks trained on ultrasonic raw Data (=radiofrequency data) for the assessment of liver diseases in patients undergoing a clinical ultrasound examination. The general feasibility is currently evaluated in a retrospective cohort.\n\nThe main questions the study aims to answer are:\n\n* Can a neuronal network trained on RF Data perform equally good as elastography in the assessment of diffuse liver diseases?\n* Can a neuronal network trained on RF Data perform better than a neuronal network trained on b-mode images in the assessment of diffuse liver diseases?\n* Can a neuronal network trained on RF Data distinguish focal pathologies in the liver from healthy tissue?\n\nTo answer these questions participants with a clinically indicated fibroscan will undergo:\n\n* a clinical elastography in Case ob suspected diffuse liver disease\n* a reliable ground truth (if normal ultrasound is not sufficient e.g. contrast enhanced ultrasound, biopsy, MRI or CT) in case of focal liver diseases, depending on the standard routine of the participating center\n* a clinical ultrasound examination during which b-mode images and the corresponding RF-Data sets are captured",[555,556,557,558,559],"Artificial Intelligence","Ultrasonography","Elasticity Imaging Techniques","Liver Diseases","Metastasis to Liver",[561,562],"Quantitative Ultrasound","Radiofrequency Data","2025-08-18",{"date":505,"type":38},{"date":566,"type":38},"2024-04-01",{"date":568,"type":22},"2025-12",{"name":44,"class":45},{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":575,"acronym":576,"eligibilityCriteria":577,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":353,"enrollmentInfo":578,"targetDuration":4,"studyType":80,"phases":580,"briefSummary":581,"conditions":582,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":585,"startDateStruct":587,"completionDateStruct":589,"leadSponsor":591,"locationsCount":220},"100571262","phase-2-prospective-evaluation-of-ivosidenib-maintenance-following-allogeneic-stem-cell-transplantation-in-patients-with-acute-myeloid-leukemia-or-high-risk-myelodysplastic-neoplasia-with-idh1-isocitrate-dehydrogenase-1-mutation-100571262","NCT06717958","Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation","A Prospective, Single-arm, Open-label, Multicenter Phase II Trial Evaluating the Efficacy and Safety of Ivosidenib Maintenance Therapy After Allogeneic Stem Cell Transplantation (alloSCT) in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Neoplasia (MD) Carrying an IDH1 Mutation","PIVOT","Inclusion criterion:\n\n* AML or MDS with IDH1 mutation\n\nExclusion criteria:\n\n* active GvHD (graft vs host disease) grade III-IV according to Harris criteria requiring steroids \\>1mg\u002F kg prednisolone equivalent",{"count":579,"type":22},76,[82],"maintenance of AML or MDS patients with known IDH1 mutation after allogeneic stem cell transplantation within past 100 days",[362,583],"MDS","2025-06-27",{"date":586,"type":38},"2025-07-02",{"date":588,"type":38},"2025-06-17",{"date":590,"type":22},"2030-02-01",{"name":44,"class":45},{"id":593,"slug":594,"hasResults":12,"nctId":595,"briefTitle":596,"officialTitle":597,"acronym":598,"eligibilityCriteria":599,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":600,"targetDuration":4,"studyType":80,"phases":601,"briefSummary":602,"conditions":603,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":120},"100569587","phase-2-gilteritinib-in-combination-with-venetoclax-and-azacitidine-for-aml-patients-with-flt3-mutations-ineligible-for-intensive-treatment-100569587","NCT06696183","Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment","Sequential Gilteritinib in Combination With Venetoclax and Azacitidine for Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and FLT3 Mutations Ineligible for Intensive Treatment","SEQUENCE","Main Inclusion Criteria:\n\n* Newly diagnosed AML (according to WHO 2022 or ICC 2022 criteria) with a minimum BM blast count of \\>=20%, excluding APL\n* FLT3 mutation at initial diagnosis\n* Ineligibility of standard induction chemotherapy\n* Pre-treatment with approved combination of Venetoclax + Azacitidine (one cycle only)\n\nMain Exclusion Criteria:\n\n* R\u002FR AML\n* Previous treatment for AML (except HU and\u002For one cycle VEN+AZA according to SOC)\n* Previous treatment with Gilteritinib\n* Known active CNS involvement\n* QTcF \\>450 ms or long QT Syndrome at screening\n* Treatment with concomitant strong CYP3A inducers or St. John's wort",{"count":164,"type":22},[82],"Explore the best tolerable and efficacious dose of Gilteritinib when combined with standard treatment with Venetoclax and Azacitidine in AML patients with FLT3 mutations which are ineligible for intensive chemotherapy",[335],"2025-05-27",{"date":606,"type":38},"2025-05-29",{"date":608,"type":38},"2025-04-25",{"date":610,"type":22},"2030-04",{"name":44,"class":45},{"id":613,"slug":614,"hasResults":12,"nctId":615,"briefTitle":616,"officialTitle":616,"acronym":617,"eligibilityCriteria":618,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":619,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":621,"conditions":622,"keywords":626,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":628,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":633,"locationsCount":404},"100489379","response-prediction-of-hyperthermic-intraperitoneal-chemotherapy-in-gastro--intestinal-cancer-100489379","NCT05652348","Response Prediction of Hyperthermic Intraperitoneal Chemotherapy in Gastro- Intestinal Cancer","Hi-STEP1","Inclusion Criteria:\n\n* (Suspected) synchronous or metachronous peritoneal metastasis of adenocarcinoma of the stomach \u002F gastroesophageal junction (GEJ) or of the colon or rectum\n* intraoperative histological confirmation of synchronous or metachronous peritoneal carcinomatosis in gastric carcinoma (incl. GEJ) or colon carcinoma (incl. rectal carcinoma)\n* Intraoperative peritoneal cancer index (PCI) ≤ 15 for gastric carcinoma and ≤ 20 for colon carcinoma.\n* Possibility of surgical resection of peritoneal carcinomatosis (cytoreductive surgery) in curative intention with achievement of a Completeness of Cytoreduction Score (CCS) of 0-1\n* No contraindication to surgery\n* No contraindication against the performance of HIPEC\n* Expected survival of 6 months at least\n* ECOG ≤ 2\n* Female and male patients ≥ 18 years of age\n* Patient is able and willing to give written informed consent and comply with the study protocol\n\nExclusion Criteria:\n\n* Presence of non-resectable distant metastases\n* Patients with extensive metastasis (e.g., multiple bilobular liver metastases, hepatic and pulmonary metastases, multiple retroperitoneal lymph node metastases; oligometastasis is allowed)\n* Patients with recurrence of peritoneal carcinomatosis (e.g., previous peritonectomy in the course of primary tumor resection)\n* Patients after previous palliative chemotherapy or radiation of the tumor (exception: neoadjuvant and\u002For adjuvant therapies)\n* Hypersensitivity\u002Fallergy to components of the planned intraperitoneal chemotherapy\n* Patients not eligible for surgery\u002FHIPEC (e.g., heart failure NYHA ≥III, myocardial infarction within the last 3 months before surgery, high-risk cardiac arrhythmias)\n* Secondary malignant disease that occurred \\\u003C5 years ago (exception: early stage of a localized tumor with in-sano resection, for example in situ carcinoma of the cervix, Adequately treated basal cell carcinoma of the skin)\n* Patients who are housed in a closed facility\n* Pregnant or breastfeeding patients, or patients who plan to become pregnant within 7 Months after the end of treatment to become pregnant",{"count":620,"type":22},48,"Patients with gastric or colon cancer with peritoneal carcinomatosis will receive a biopsy of the tumor during their primary curative surgery. The operation is performed according to standard and includes resection of the primary tumor and any metastases and followed by HIPEC (Intraperitoneal hyperthermic chemoperfusion) according to the respective hospital standard. Organoid cultures from the biopsies are established in the research laboratory.\n\nVarious chemotherapeutic agents are tested on these tumor organoids in the laboratory and the tumor organoids are analyzed in detail with regard to genetic alterations in order to find alterations that can be addressed, if necessary, by means of targeted drugs against peritoneal carcinomatosis.",[623,624,625],"Gastric Cancer","Colon Cancer","Peritoneal Carcinomatosis",[627],"Organoid",{"date":606,"type":38},{"date":630,"type":38},"2022-12-08",{"date":632,"type":22},"2028-12-31",{"name":44,"class":45},{"id":635,"slug":636,"hasResults":12,"nctId":637,"briefTitle":638,"officialTitle":639,"acronym":640,"eligibilityCriteria":641,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":642,"targetDuration":4,"studyType":80,"phases":644,"briefSummary":645,"conditions":646,"keywords":650,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":659,"lastUpdatePostDateStruct":660,"startDateStruct":661,"completionDateStruct":663,"leadSponsor":665,"locationsCount":120},"100591889","radiation-induced-toxicity-of-the-heart-100591889","NCT06986291","Radiation-induced Toxicity of the Heart","Quantitative Assessment of Radiation-induced Toxicity of the Heart","CorTox","Inclusion Criteria:\n\n* Patients 18 years old or older\n* Patient's consent and written consent is available\n* Patients with the non-small cell lung cancer or esophageal cancer or breast cancer who have an indication for intended curative radio(chemo)therapy (in the case of breast cancer inclusion of female patients only)\n\nExclusion Criteria:\n\n* Patients who are not capable of giving consent\n* Pregnant women\n* Patients with contraindications for MRI examinations (pacemakers, defibrillators, neurostimulators, aneurysm clips, cochlear implants, permanent make-up, metal splinters or osseosynthetic implants)\n* Patients with insufficient kidney function (glomerular filtration rate (GFR) of less than 30 ml\u002Fmin)\n* Patients with the aforementioned tumour entities for whom a palliative indication exists",{"count":643,"type":22},325,[222],"Late side effects in radio(chemo)therapy \\[R(CH)T\\] pose a critical limitation to patients' overall survival and quality of life. Even though toxicities of the heart are highly relevant for patients with cancer in the thoracic region, risk stratification models for these toxicities are lacking. In this study, liquid, functional and imaging biomarkers are being investigated for their use in prediction of cardiac toxicity following R(CH)T for patients with thoracic malignancies.",[647,648,649],"Non-small Cell Lung Cancer","Esophageal Cancer","Breast Cancer Female",[651,652,653,654,655,656,657,658],"Non-small cell lung cancer","Esophageal cancer","Breast cancer","Cardiotoxicity","Radio(chemo)therapy","MRI","Cardiac function test","Omics analyses","2025-05-22",{"date":606,"type":38},{"date":662,"type":22},"2025-08",{"date":664,"type":22},"2039-12",{"name":44,"class":45},{"id":667,"slug":668,"hasResults":12,"nctId":669,"briefTitle":670,"officialTitle":671,"acronym":672,"eligibilityCriteria":673,"healthyVolunteers":549,"sex":18,"minAge":674,"maxAge":19,"enrollmentInfo":675,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":677,"conditions":678,"keywords":680,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":690,"lastUpdatePostDateStruct":691,"startDateStruct":693,"completionDateStruct":695,"leadSponsor":697,"locationsCount":698},"100367605","neurocognitive-function-after-proton-therapy-in-children-and-adolescents-100367605","NCT04066465","Neurocognitive Function After Proton Therapy in Children and Adolescents","Neurocognitive Function \u002Fexecutive Functions After Proton Therapy in Children and Adolescents.","ELBE-ProKids","Indication: Patients with primary brain tumor\n\nInclusion Criteria:\n\n* all groups: Patients in childhood and adolescence between 8-18 years of age\n* all groups: no prior radiotherapy of the brain,\n* all groups: The patient is able to perform repeated neuropsychological tests (approx. 1 hour per examination),\n* all groups: corrected visual acuity not impaired below 80% or no subjective indication of visual acuity impairment,\n* all groups: corrected hearing not impaired or no subjective evidence of hearing impairment,\n* all groups: Patient is able to perform follow-up examinations,\n* all groups: written consent of the patient\u002Fparent or guardian.\n* Brain tumour groups with\u002Fwithout irradiation: Primary brain tumour\n* brain tumor groups with\u002Fwithout radiation: curative or long-term palliative intention of therapy\n* brain tumor groups with\u002Fwithout irradiation: life expectancy \\> 3 years\n* Irradiation group only: planned proton therapy with a local radiation dose of at least 40 Gy(RBE)\n\nExclusion Criteria:\n\n* Patients under 8 or over 18 years of age (We limit the study to children over 8 years of age due to the fact that executive functions mature very late.)\n* Brain metastases from extracerebral tumors\n* Patient receives intrathecal chemotherapy\n* pure palliative treatment concept\n* The patient is not able to perform repeated neuropsychological tests (approx. 1 hour per examination).\n* Chronic diseases that may affect the results of neurological EEG and neuropsychological examinations.\n* The patient is not in a position to perform follow-up examinations\n* no written consent of the patient \u002F parent or legal guardian\n* Participation in an intervention study whose procedures contradict those of the present study","8 Years",{"count":676,"type":22},90,"Brain tumors are the second most frequent malignant diseases in children and adolescents. In the study the short and medium term consequences of proton therapy on cognitive processes in particular on executive functions in pediatric patients shall be highlighted\u002Fanalysed\u002Fevalutated. In a second step, these results are to be compared with\n\n1. a group of children and adolescents who had only \u002Fexclusively had operative therapy and\n2. with a healthy control group. Thus, the extent to which these treatment options differ in terms of their short and medium-term effect is assessed. Methods of neurocognitive\u002Fneurophysiology brain research approaches are applied that may potentially visualize even small \u002F subtle changes in mental activities\u002Fneurocognitive function. Therefore the effects of treatment can be evaluated and the neuropsychological outcome of children and adolescents with brain tumors can be improved.",[679],"Primary Brain Tumor",[681,682,683,684,685,686,687,688,689],"Brain Tumor","children and adolescents","neurocognitive function","neurocognitive or neuropsychological outcome","quality of life, LOQ","EEG","Neuropsychological Tests","Proton Therapy","Neurosurgical Treatment","2025-02-04",{"date":692,"type":38},"2025-02-06",{"date":694,"type":38},"2019-09-01",{"date":696,"type":22},"2027-12-31",{"name":44,"class":45},3,""]